Morphinsulfat Ps Pharma (Morphine Sulfate)

Morphine sulfate binds to mu‑opioid receptors in the brain and spinal cord, activating them to inhibit the release of pain‑transmitting neurotransmitters. This reduces neuronal excitability, leading to decreased perception of pain and a calming, sedative effect.

The appropriate dose of morphine sulfate is individualized by the prescribing clinician based on the patient’s pain intensity, prior opioid exposure, age, organ function, and other clinical factors. Dosage regimens are not standardized and must follow a qualified prescriber’s instructions.

Safety of morphine sulfate in pregnancy or while breastfeeding has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Morphine sulfate is considered a benchmark opioid due to its well‑characterized efficacy and safety profile. Compared with newer synthetic opioids, it has a longer history of use, predictable pharmacokinetics, and is often less expensive, but it shares similar risks of respiratory depression and dependence.

Morphinsulfat Ps Pharma should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

The product is formulated for oral administration. It may be supplied as tablets, capsules, or liquid, and should be taken exactly as prescribed, usually with a glass of water. Swallow whole unless the prescriber advises otherwise.

The most serious risks include respiratory depression, severe hypotension, profound sedation, and the potential for dependence, abuse, or addiction. Prompt medical attention is required if breathing becomes shallow, blood pressure drops markedly, or signs of overdose appear.

Morphine sulfate is contraindicated in patients with known hypersensitivity to morphine or other opioids, those who have experienced severe respiratory depression, or individuals taking monoamine oxidase inhibitors within 14 days. Caution is also advised for patients with uncontrolled asthma or severe head injury.